

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Department of the Army</p>	<p>In accordance with letter dated February 23, 2018.</p>	<p>4. Expiration Date: July 31, 2025</p>
<p>2. Ireland Army Health Clinic 289 Ireland Avenue Fort Knox, KY 40121-5111</p>	<p>3. License number: 16-03657-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-01748 Reference No.:</p>

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1500 millicuries total	C. Any Iodine-131 diagnostic study therapy procedure permitted by 10 CFR 35.300
D. Any byproduct material permitted by 10 CFR 35.500	D. Sealed Sources (DuPont Merck, Model NES 8412; Isotopes Products Laboratories, Inc., Model A3410, or equivalent; North American Scientific, Model MED 3601)	D. 300 millicuries per source and 1500 millicuries total	D. For diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered in accordance with 10 CFR 30.32(g).

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
16-03657-01

Docket or Reference Number
030-01748

Amendment No. 74

- | | | | |
|---|----------------------------------|--|---------------------------------|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| E. Any byproduct material permitted by 10 CFR 31.11 | E. Prepackaged Kits | E. 200 microcuries total | E. For use in in-vitro studies. |

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at Ireland Army Community Hospital, 289 Ireland Avenue, Fort Knox, Kentucky.
11. The Radiation Safety Officer (RSO) for this license is CPT Monique M. McIver .
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User(M.D.,D.O.,etc.)</u> | <u>Material and Use</u> |
|--|---|
| MAJ Tina Mascarenhas | 35.100; 35.200; Oral administration of sodium iodide iodine-131; 35.500, In vitro studies |
| MAJ Aimee M. Wilson, MD.. | 35.100; 35.200; Oral administration of sodium iodide iodine-131; In vitro studies |
13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
16-03657-01

Amendment No. 74

Docket or Reference Number
030-01748

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Letter dated November 9, 2004 [ML050110347]
- B. Letter dated January 24, 2005 [ML050380053]
- C. Letter dated October 6, 2016 [ML16293A081]
- D. Letter dated March 13, 2017 [ML17097A267]

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: May 8, 2018By: Farrah Gaskins
Region 1